607 related articles for article (PubMed ID: 8691835)
1. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
2. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
von Kleist S; Hesse Y; Kananeeh H
Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564
[TBL] [Abstract][Full Text] [Related]
5. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
7. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
11. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
12. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
[TBL] [Abstract][Full Text] [Related]
13. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
15. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of quarterly assessment of CEA, TPA and GICA serum levels in gastric and colorectal carcinomas: Prospective study of 174 patients undergoing radical surgery].
Barillari P; Ricci M; Broglia S; Manetti G; Cerasi A; Cesareo S; Calcaterra D; Cioè I; Caronna R; Sammartino P
Minerva Chir; 1994 Oct; 49(10):953-61. PubMed ID: 7808670
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
19. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Grotowski M
Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
